Select all that apply
Select all that apply
Lyophilization: Protecting and preserving biologics
Lyophilization, also known as freeze-drying, is often a crucial step in the manufacturing process of biologics drug products. Biologics are large, complex molecules used to treat various diseases, including cancer, autoimmune disorders, and rare gene...
Rapid discovery and characterization of monoclonal antibodies against the SARS-CoV-2 Delta spike protein
In the fall of 2021, the Delta variant of SARS-CoV-2 was the dominant strain in the US, being both more contagious than previous variants and more likely to lead to “long COVID” than subsequent Omicron variants. Here we describe the discovery and...
Overcome a “lack of time” challenge
To say that “our lives are busier than ever” would be a redundant statement. The good news is: we still have 24 hours in each day! Curia’s Director, Learning & Development, Terri Souder-Basa put together a practical guide on how to overcome a...
How T3P is helping to advance API development
The right choice of organic reagents early in the synthesis can smooth the path and expediate the journey of lead- to- candidate identification. Curia can produce the green and versatile reagent T3P in a superior purity – and give researchers the f...
The value of engaging a single CDMO for comprehensive biologics services from discovery to GMP manufacturing
A large portion of innovative companies are in discovery, preclinical or early clinical stages with therapeutics aimed at oncology and infectious diseases. There is promising growth in overall biologics therapies, driven by increased funding and grow...
The current and future value of mRNA vaccines and therapeutics
With experience in both chemistry and biologics, Curia is uniquely positioned to provide mRNA drug development solutions spanning discovery and engineering, mRNA drug substance formulation, and fill-finish and manufacturing of lipids and nucleosides.
Outsourcing Your Parenteral Manufacturing – Choosing the Optimal CDMO
When a drug substance requires a parenteral formulation to administer it, there are key factors to consider when choosing the ideal CDMO partner.
Accelerated API manufacturing by combining early-stage and late-stage process development
Traditionally, early-stage and late-stage process development have been done separately, with early-stage mostly focused on material production and late-stage on process intensification. As more molecules in development fall under an orphan or fast-t...
Leveraging efficiency from cell line development to clinical manufacturing of monoclonal antibodies
The number of FDA-approved monoclonal antibodies (mAbs) continues to grow, while those in late-stage development rose more than 30% between 2021 and 2022.
Leveraging the immunological diversity of the PentaMice® platform for COVID-19 antibody discovery
Hybridoma technology is a popular method for antibody discovery, but the conventional approach of using a single inbred mouse strain for immunization fails to generate the diversity and antibody titers needed to maximize the discovery of high-quality...
Antibody-based drug discovery at the speed of light
The combination of the PentaMice® platform and single B cell screening with the Berkeley Lights Beacon® Optofluidic system increases speed to market for monoclonal antibody therapeutics.
The benefits of end-to-end formulation and fill-finish of biologics
The clinical value of biologics for the treatment of many disease indications has been accompanied by phenomenal sales. By 2026, the global market for biologics is projected to increase to $537 billion. However, getting a promising drug candidate fro...